Skip to main content

Table 1 Patient demographics and baseline characteristics (randomized population)

From: Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)

  Rosuvastatin 10 mg (n = 504) Atorvastatin 20 mg (n = 492)
Mean age, years (SD) 60.2 (10.4) 60.7 (10.6)
Male gender, n (%) 273 (54.2) 285 (57.9)
Mean BMI, kg/m2 (SD) 29.7 (5.6) 29.7 (5.9)
Race, n (%)   
   Caucasian 376 (74.6) 380 (77.2)
   Hispanic 98 (19.4) 90 (18.3)
   Black 23 (4.6) 17 (3.5)
   Asian 6 (1.2) 3 (0.6)
   Other 1 (0.2) 2 (0.4)
Renal function*, n (%)   
   Normal 292 (57.9) 271 (55.1)
   Mild impairment 177 (35.1) 190 (38.6)
   Moderate impairment 35 (6.9) 29 (5.9)
Metabolic syndrome, n (%) 254 (50.4) 237 (48.2)
Diabetes (type 1 or 2), n (%) 256 (50.8) 250 (50.8)
CHD or CHD-risk equivalents, n (%) 431 (85.5) 407 (82.7)
Patients without CHD or a CHD-risk equivalent, n (%) 72 (14.3) 85 (17.3)
   Framingham 10-year risk > 20% 30 (6.0) 32 (6.5)
   Framingham 10-year risk ≥ 10% and ≤ 20% 17 (3.4) 25 (5.1)
   Framingham 10-year risk < 10% 25 (5.0) 28 (5.7)
  1. SD, standard deviation; BMI, body mass index; CHD, coronary heart disease; NCEP ATP, National Cholesterol Education Program Adult Treatment Panel; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.
  2. *Renal function assessed using creatinine clearance as follows: > 80 mL/min (normal), 50 to ≤ 80 mL/min (mild impairment), 30 to < 50 mL/min (moderate impairment). Creatinine clearance was calculated from serum creatinine using the following equations: creatinine clearance (mL/min) = ([140-age at visit 4] × weight at visit 1 [kg])/72 × serum creatinine at visit 4 (mmol/L) × 0.01131 if male; or creatinine clearance (mL/min) = ([140-age at visit 4] × weight at visit 1 [kg])/85 × serum creatinine at visit 4 (mmol/L) × 0.01131 if female.
  3. Modified NCEP ATP III definition [6]: Patients fulfill at least 3 of the following 5 criteria: fasting blood glucose ≥ 6.1 and ≤ 6.9 mmol/L (110 and 125 mg/dL); waist circumference > 102 cm (male) or > 88 cm (female); TG ≥ 1.7 mmol/L (150 mg/dL); HDL-C < 1.0 mmol/L (40 mg/dL) in men or < 1.3 mmol/L (50 mg/dL) in women; and hypertension (SBP ≥ 130 mmHg or DBP ≥ 85 mmHg) or taking antihypertensive medication.